Endocyte

Company

Related News

Artios expands leadership team as alnodesertib moves toward late-stage development

May 05, 2026

Artios added six senior leaders in 2026 as alnodesertib moved toward late-stage development and potential U.S. commercialization. The company is also running a Phase 2 study of ART6043.

Olema appoints Prakash Raman to board as it advances oncology pipeline

May 03, 2026

Olema Pharmaceuticals appointed Prakash Raman, Ph.D., to its board of directors. The company said the oncology deal veteran joins as Olema advances palazestrant and OP-3136 while remaining loss-making.